LogicBio Therapeutics (LogicBio Therapeutics) Shares Outstanding (Diluted Average) : 32.96 Mil (As of Jun. 2022)

View and export this data going back to 2018. Start your Free Trial

What is LogicBio Therapeutics Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. LogicBio Therapeutics's average diluted shares outstanding for the quarter that ended in Jun. 2022 was 32.96 Mil.

LogicBio Therapeutics Shares Outstanding (Diluted Average) Historical Data

The historical data trend for LogicBio Therapeutics's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LogicBio Therapeutics Shares Outstanding (Diluted Average) Chart

LogicBio Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Shares Outstanding (Diluted Average)

Get a 7-Day Free Trial

13.67

5.80

22.60

25.36

32.38

LogicBio Therapeutics Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Shares Outstanding (Diluted Average)	Get a 7-Day Free Trial															32.16	32.44	32.96	32.96	32.96

LogicBio Therapeutics Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

LogicBio Therapeutics (NAS:LOGC) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

LogicBio Therapeutics Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of LogicBio Therapeutics's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

LogicBio Therapeutics (LogicBio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LogicBio Therapeutics Inc (NAS:LOGC) » Definitions » Shares Outstanding (Diluted Average)

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Hayden Avenue, 2nd Floor, Lexington, MA, USA, 02421

Website

https://www.logicbio.com

LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301.

Executives

Mark J Enyedy	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Mariana Nacht	officer: Chief Scientific Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Daniel Gruskin	officer: Chief Medical Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Susan Kahn	director	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Joshua Blacher	officer: Interim CFO	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Andrea Paul	officer: General Counsel and Secretary	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Frederic Chereau	director, officer: See Remarks	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Kyle Chiang	officer: Chief Operating Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Cecilia Jones	officer: Chief Financial Officer	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jonathan Quick	officer: Senior Director-Finance	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jeff Goater	director	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Erez Chimovits	director	P.O. BOX 4023, HERZLIYA PITUACH L3 4614001
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022